Antioxidant targeting by deferiprone in diseases related to oxidative damage

Frontiers in Bioscience - Landmark

Volumn 19, Issue 6, 2014, Pages 862-885

  Kontoghiorghe, Christina N ^a   Kolnagou, Annita ^a   Kontoghiorghes, George J ^a  

^a Postgraduate Research Institute of Science Technology Environment and Medicine Limassol   (Cyprus)

Author keywords

Antioxidant therapy; Antioxidants; Chelators; Copper; Deferasirox; Deferiprone; Deferoxamine; Free radical toxicity; Iron; Metal ions; Review; Targeting

Indexed keywords

ANTIOXIDANT; DEFERIPRONE; FREE RADICAL; IRON CHELATING AGENT; PYRIDONE DERIVATIVE;

ACUTE KIDNEY FAILURE; ANTAGONISTS AND INHIBITORS; CARDIOMYOPATHY; DRUG EFFECTS; FRIEDREICH ATAXIA; HUMAN; IRON OVERLOAD; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PHYSIOLOGY;

ACUTE KIDNEY INJURY; ANTIOXIDANTS; CARDIOMYOPATHIES; FREE RADICALS; FRIEDREICH ATAXIA; HUMANS; IRON CHELATING AGENTS; IRON OVERLOAD; OXIDATIVE STRESS; PYRIDONES;

EID: 84904313432     PISSN: 27686701     EISSN: 27686698     Source Type: Journal    
DOI: 10.2741/4253     Document Type: Review

References (131)

1. Denisov, E.T., and I.B. Afanas'ev: Oxidation and antioxidants in organic chemistry and biology. CRC Press, Taylor and Francis group. Boca Raton. (2005)
2. Halliwell, B., J.M.C.Gutteridge, and C.E. Cross: Free radicals, antioxidants and human disease: Where are we now? J Lab Clin Med 119, 598-620 (1992)
3. Kontoghiorghes, G.J.: Iron chelation in biochemistry and medicine. Ed: Rice-Evans C., Rechelieu Press, London."Free radicals, oxidant stress and drug action". 277-303 (1987)
4. Kontoghiorghes, G.J.: Prospects for introducing deferiprone as potent pharmaceutical antioxidant. Front Biosci (Elite Ed) 1, 161-178 (2009)
5. Karogodina, T.Y., S.V.Sergeeva and Stass, D.V.: Stability and reactivity of free radicals: a physicochemical perspective with biological implications. Hemoglobin 35, 262-275(2011)
6. Kontoghiorghes, G.J., A. Efstathiou, M. Kleanthous, Y. Michaelides and Kolnagou, A: Risk/benefit assessment, advantages over other drugs and targeting methods in the use of deferiprone as a pharmaceutical antioxidant in iron loading and non iron loading conditions. Hemoglobin 33, 386-397 (2009)
7. Jeremy, J.Y., J. Gill, T. Prior, G. Sifakis M.A. Barradas, and G.J. Kontoghiorghes: Inhibition of cyclooxygenase and lipoxygenase activity by iron chelators: Possible use in the treatment of eicosanoid-related disorders. Drugs Today 28 (Suppl A), 35-43 (1992)
8. Stangherlin, A. and A.B. Reddy: Regulation of circadian clocks by redox homeostasis. J Biol Chem. (2013) [Epub ahead of print]
9. Lu S.C.: Glutathione synthesis. Biochim Biophys Acta 830, 3143-3153 (2013)
10. Korkina, L.G. and I.B. Afanas'ev: Antioxidant and chelating properties of flavonoids. Adv Pharmacol 38, 151-163. (1997)
11. Maher P.: The flavonoid fisetin promotes nerve cell survival from trophic factor withdrawal by enhancement of proteasome activity. Arch Biochem Biophys 476, 139-144 (2008)
12. Halliwell, B.: Free radicals and antioxidants: updating a personal view. Nutr Rev 70, 257-265 (2012)
13. Kitazawa, M., K. Iwasaki and K. Sakamoto: Iron chelators may help prevent photoaging. J Cosmet Dermatol 5, 210-217 (2006)
14. Afanas'ev, I.B.: Superoxide and nitric oxide in pathological conditions associated with iron overload. The effects of antioxidants and chelators. Curr Med Chem 12, 2731-2739 (2005)
15. Kontoghiorghes, G.J., K. Neocleous, and A. Kolnagou: Benefits and risks of deferiprone in iron overload in thalassaemia and other conditions. Drug Safety 26, 553-584 (2003)
16. Kontoghiorghes, G.J.: Iron mobilization from transferrin and non-transferrin bound iron by deferiprone. Implications in the treatment of thalassaemia, anaemia of chronic disease, cancer and other conditions. Hemoglobin 30, 183-200 (2006)
17. Kontoghiorghes, G.J., and A. Kolnagou: Molecular factors and mechanisms affecting iron and other metal excretion or absorption in health and disease. The role of natural and synthetic chelators. Curr Med Chem 12, 2695-2709 (2005)
18. Cai, L., X.K. Li, Y.Song, and M.G. Cherian: Essentiality, toxicology and chelation therapy of zinc and copper. Curr Med Chem 12, 2753-2763 (2005)
19. Kontoghiorghes, G.J., E. Eracleous, C. Economides and A. Kolnagou: Advances in iron overload therapies. Prospects for effective use of deferiprone (L1), deferoxamine, the new experimental chelators ICL670, GT56-252, L1NAll and their combination. Curr Med Chem 12, 2663-2681 (2005)
20. Kyriacou, K.Y., Michaelides, R. Senkus, K. Simamonian, N. Pavlides, L. Antoniades, and C. Zambartas: Ultrastructural pathology of the heart in patients with beta- thalassaemia major. Ultrastruct Pathol 24, 75-81 (2000)
21. Iancu, T.C., and H.B. Neustein: Ferritin in human liver cells of homozygous beta-thalassaemia: ultrastructural observations. Br J Haematol 37, 527-535 (1977)
22. Blanusa, M., V.M. Varnai, M Piasek, and K. Kostial: Chelators as antidotes of metal toxicity: therapeutic and experimental aspects. Curr Med Chem 12, 2771-2794 (2005)
23. Sargent, P.J., S. Farnaud, and R.W. Evans: Structure/function overview of proteins involved in iron storage and transport. Curr Med Chem 12, 2683-2693 (2005)
24. Sheppard, L., and G.J. Kontoghiorghes: Competition between deferipone, desferrioxamine and other chelators for iron and the effect of other metals. Arzheim- Forsch/Drug Res 43:659-663 (1993)
25. Pippard, M.J., M.J. Jackson, K.Hoffman, M. Petrou and C.B. Modell: Iron chelation using subcutaneous infusion of diethylene triamine penta-acetic acid (DTPA) Scand J Haematol 36, 466-472 (1986)
26. De Virgilis, S., M.Cognia, M.P. Turco, F.Frau, C.Dessi, F. Argiolou, R. Sorcinelli, A. Sitzia, and A.Cao: Depletion of trace elements and acute occular toxicity induced by desferrioxamine in patients with thalassaemia. Arch Dis Child, 250-255 (1988)
27. AlRefai, F.N., B.Wonke, D.G. Wickens, Y. Aydinok, A. Fielding, and A.V. Hoffbrand: Zinc concentration in patients with iron overload receiving oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one or desferrioxamine. J Clin Pathol 47:657-660 (1994)
28. Yamamoto, R.S., G.M. Williams, H.H. Frangel, and J.H. Weisburger: 8-hydroxyquinoline: chronic toxicity and inhibitory effect on the carcinogenicity of N-2- fluorenylacetamide. Toxicol Appl Pharmacol 19, 687-698 (1971)
29. Mostert, L.J., J.A.L.M. Van Dorst, J.F. Koster, H.G.Van Eijk, and G.J. Kontoghiorghes: Free radical and cytotoxic effects of chelators and their iron complexes in the hepatocyte. Free Rad Res Comms 3: 379-388 (1987)
30. Kontoghiorghes, G.J., J.Barr, and R.A. Baillod: Studies of aluminium mobilisation in renal dialysis patients using the oral chelator 1, 2-dimethyl-3-hydroxypyrid-4-one. Arzn.Forsch/Drug Res 44: 522-526 (1994)
31. Kontoghiorghes, G.J., M.A.Aldouri, A.V. Hoffbrand, J. Barr, B. Wonke, T. Kourouklaris, and L. Sheppard: Effective chelation of iron in betathalassaemia with the oral chelator 1, 2-dimethyl-3-hydroxypyrid-4-one. Br Med J 295: 1509-1512 (1987)
32. Kontoghiorghes, G.J.: Chelators affecting iron absorption in mice. Arzn.Forsch/Drug Res 40, 1332-1335 (1990)
33. Kontoghiorghes, G.J., M.I. Jackson, and J. Lunec: In vitro screening of iron chelators using models of free radical damage. Free Rad Res Comms 2: 115-124 (1986)
34. Srichairatanakool, S., S.Ounjaijean, C. Thephinlap, U. Khansuwan, C.Phisalpong, and S. Fuchareon: Ironchelating and free-radical scavenging activities in microwave processed green tea in iron overload. Hemoglobin 30, 311- 327 (2006)
35. Kontoghiorghes, G.J.: The design of orally active iron chelators for the treatment of thalassaemia. PhD thesis, University of Essex, Colchester UK. British Library Microfilm No D66194/86. 1982: 1-243
36. Kontoghiorghes, G.J.: Design, properties and effective use of the oral chelator L1 and other α- ketohydroxypyridines in the treatment of transfusional iron overload in thalassaemia. Ann NY Acad Sci 612, 339-350 (1990)
37. Kontoghiorghes, G.J., K. Pattichis, K. Neocleous, and A. Kolnagou: The design and development of deferiprone (L1) and other iron chelators for clinical use: Targeting methods and application prospects. Curr Med Chem 11, 2161-2183 (2004)
38. Kontoghiorghes, G.J., L. Sheppard, and S. Chambers: New synthetic approach and iron chelation studies of 1-alkyl-2-methyl-3-hydroxypyrid-4-ones. Arz.Forsch/Drug Res 37, 1099-1102 (1987)
39. Pashalidis, I., and G.J. Kontoghiorghes: Molecular factors affecting the complex formation between deferiprone (L1) and Cu (II) Arz.Forsch/Drug Res 51, 998- 1003 (2001)
40. Pashalidis, I., and G.J. Kontoghiorghes: Effective complex formation in the interaction of I,2-dimethyl-3-hydroxypyrid-4-one (Deferiprone or L1) with Uranium (VI) J Rad Nuclear Chem 242, 181-184 (1999)
41. Kontoghiorghes, G.J.: Comparative efficacy and toxicity of desferrioxamine, deferiprone and other iron and aluminium chelating drugs. Toxicol Lett 80, 1-18 (1995)
42. Kontoghiorghes, G.J., J.G. Goddard, A.N. Bartlett, and L. Sheppard: Pharmacokinetic studies in humans with the oral iron chelator 1, 2-dimethyl-3-hydroxypyrid-4-one. Clin Pharmacol Therap 48, 255-261 (1990)
43. Kontoghiorghes, G.J., A.N. Bartlett, A.V. Hoffbrand, J.G. Goddard, L.Sheppard, J.Barr, and Nortey P: Long term trial with the oral chelator 1, 2-dimethyl-3-hydroxypyrid-4-one (L1) (I) Iron chelation and metabolic studies. Br J Haematol 76, 295-300 (1990)
44. Kontoghiorghes, G.J., A.N. Bartlett, L. Sheppard, J. Barr, and P. Nortey: Oral iron chelation therapy with deferiprone (L1): Monitoring of biochemical, drug and iron excretion changes. Arzn. Forsch/Drug Res 45:65-69 (1995)
45. Sheppard, L., and G.J. Kontoghiorghes: Synthesis and metabolism of L1 and other novel alphaketohydroxypyridine iron chelators and their metal complexes. Drugs Today 28 (Suppl A): 3-10 (1992)
46. Matsui, D., J. Klein, C. Hermann, V. Grunau, R. McClelland, D. Chung, P. StLouis, N. Olivieri, and G. Koren: Relationship between the pharmacokinetics and iron excretion pharmacodynamics of the new oral iron chelator1,2-dimethyl-3- hydroxypyrid-4-one in patients with thalassaemia. Clin Pharmacol Therap 50, 294-298 (1991)
47. Nielsen, P., M. Frtjes, B. Drescow, R. Fischer, R. Engelhardt, and H.C. Heinrich: The iron-decorporating effect of L1 in normal and TMH-ferrocene iron loaded rats and in one patient with post-transfusional siderosis as judged by 59Fe-labelling technique. Drugs Today 28 (suppl.A): 45-53 (1992)
48. Diav-Citrin, O., G. Atanackovic, and G. Koren: An investigation into variability in the therapeutic response to deferiprone in patients with thalassaemia major. Therap Drug Monitor 21, 74-81 (1999)
49. Kontoghiorghes, G.J.: Clinical use, therapeutic aspects and future potential of deferiprone in thalassaemia and other conditions of iron and other metal toxicity. Drugs Today 37, 23-35 (2001)
50. Evans, R.W., M. Sharma, W. Ogwang, K.J. Patel, A.N. Bartlett, and G.J. Kontoghiorghes: The effect of alphaketohydroxypyridine chelators on transferrin saturation in vitro and in vivo. Drugs Today. 28 (Suppl A), 19-23 (1992)
51. Nielsen, P., R. Fischer, R. Engelhardt, P. Tondury, E.E. Gabbe, and G.E. Janka: Liver iron stores in patients with secondary haemochromatosis under iron chelation therapy with deferoxamine or deferiprone. Br J Haematol 9, 827-833 (1995)
52. Olivieri, N.F., G. Koren, D. Matsui, P.P. Liu, L. Blendy, R. Cameron, R.A. McClelland, D. and M. Templeton: Reduction of tissue iron stores and normalisation of serum ferritin during treatment with the oral iron chelator L1 in thalassaemia intermedia. Blood 79, 2741-2748 (1992)
53. Anderson, L.J., B. Wonke, E. Prescott, S. Holden, J.M. Walker, and D.J. Pennel: Comparison of effects of oral deferiprone and subcutaneous desferrioxamine on myocardial iron concentrations and ventricular function in beta-thalassaemia. Lancet 360, 516-520 (2002)
54. Kolnagou, A., Ch. Fessas, A. Papatryphonas, Ch. Economides, and G.J. Kontoghiorghes: Prophylactic use of deferiprone (L1) and magnetic resonance imaging T2&z.ast; or T2 for preventing heart disease in thalassaemia. Br J Haematol 127, 360-361 (2004)
55. Dresow, B., R. Fischer, P. Nielsen, E.E. Gabbe, and A. Piga: Effect of oral iron chelator L1 in iron absorption in man. Ann N Y Acad Sci 850, 466-468 (1998)
56. Kontoghiorghes, G.J., T. Bunce, and K.R. Bruckdorfer: Differentiation of the therapeutic and toxicological effects of iron and copper chelating drugs in relation to free radical toxicity. Toxicol Lett 78, 48-49 (1995)
57. Pope, E., M. Berkovitch, J. Klein, F. Fassos, and G. Koren: Salivary measurement of deferiprone concentrations and correlation with serum levels. Ther Drug Monitor 19, 95-97 (1997)
58. Hoffbrand, A.V., A. Bartlett, P.A.Veys, N.T.J. O'Connor, and G.J. Kontoghiorghes: Agranulocytosis and thrombocytopenia in a patient with Blackfan-Diamond anaemia during oral chelator trial. Lancet II: 457 (1989)
59. Loebstein, R., O. Diav-Citrin, and G. Atanackovic: Deferiprone-induced agranulocytosis: a critical review of five rechallenged cases. Clin Drug Invest 13,345-349 (1997)
60. Kontoghiorghes, G.J., A.H. Bartlett, and A.V. Hoffbrand: Prospects for effective oral iron chelation therapy in man with 1,2-dimethyl-3-hydroxypyrid-4- one and other alphaketohydroxypyridines. Prog Clin Biol Res 309, 107-114 (1989)
61. Agarwal, M.B., S.S.Gupta, C. Viswanathan, D. Vasandani, J. Ramanathan, N. Desai, R.R.Puniyani, and A.T. Chhablani: Long term assessment of efficacy and toxicity of L1 (1,2-dimethyl-3-hydroxypyrid-4-one) in transfusion dependent thalassaemia: Indian trial. Drugs Today, 28 (Suppl A) 107-114 (1992)
62. Cohen, A.R., R. Galanello, A. Piga, A. Di Palma, C. Voullo, and F. Tricta: Safety profile of the oral iron chelator deferiprone: a multicentre study. Br J Haematol 108, 305-312 (2000)
63. Henter, J.I., and J.Karlen: Fatal agranulocytosis after deferiprone therapy in a child with Diamond-Blackfan anemia. Blood 109, 5157-5159 (2007)
64. Douvas, S.G., M.H. May, A. Kolnagou, and G.J. Kontoghiorghes: Effects on Mycobacterium avium replication in normal human macrophages by deferiprone (L1) and other iron chelators. Possible implications on toxicity. Arzn.Forsch/Drug Res 52, 45-52 (2002)
65. Reeder, B.J., and M.T. Wilson: Hemoglobin and myoglobin associated oxidative stress: from molecular mechanisms to disease states. Curr Med Chem 12, 2741- 2751 (2005)
66. Saleem, M.M., and M.T.Wilson: Kinetic studies on the reduction of cytochrome c. Reaction with dihydroxyconjugated compounds (catechols and quinols) Biochem J 20, 433-444 (1982)
67. Kontoghiorghes, G.J.: Orally active á-ketohydroxypyridine iron chelators. Effects on iron and other metal mobilisations. Acta Haematol 78, 212-236 (1987)
68. Moridani, M.Y., and P.J. O'Brien: Iron complexes of deferiprone and dietary plant catechols as cytoprotective superoxide radical scavengers. Biochem Pharmacol 62, 1579-1585 (2001)
69. Chakraborty, D., and M. Bhattacharrya: Deferiprone (L1) induced conformation change of hemoglobin: A fluorescence and CD spectroscopic study. Mol Cell Biochem 204, 17-20 (2000)
70. Korkina, L., C. De Luca, I. Deeva, S. Perrota, B. Nobili, P.Passi, and P. Puddui : L1 effects on reactive oxygen (ROS) and nitrogen species (RNS) release, haemoglobin oxidation, low molecular weight antioxidants, and antioxidant enzyme activities in red and white blood cells of thalassaemic patients. Transfus Sc 23, 253-254 (2000)
71. Tsukamoto, H.: Iron regulation of hepatic macrophage TNFalpha expression. Free Radic Biol Med 32, 309-313 (2002)
72. Van, A.M.M., der Kraaij, H.G.Van Eijk, and J.F. Koster: Prevention of postischemic cardiac injury by the orally active iron chelator 1,2-dimethyl-3-hydroxy-4-pyridone (L1) and the antioxidant (+)-cyanidanol-3. Circulation 80,158-164 (1989)
73. Barnabe, N., J.A. Zastre, S. Venkataram, and B.B. Hassinof.: Deferiprone protects against doxorubicin-induced myocyte cytotoxicity. Free Rad Biol Med 33, 266-275 (2002)
74. Hanauske-Abel, H.M., T.A. McCaffrey, and R. Grady: Protein hydroxylation inhibitors for fibroproliferative disorders. WO 9622021
75. Jeremy, J.Y., G.J.Kontoghiorghes, A.V. Hoffbrand, and P. Dandona: The iron chelators desferrioxamine and 1-alkyl-methyl-3-hydroxypyrid-4-ones inhibit vascular prostacylin synthesis in vitro. Biochem J. 254, 239-244 (1988)
76. Barradas, M.A., J.Jeremy, G.J. Kontoghiorghes, D.P.Michailidis, A.V.Hoffbrand, and P. Dandona: Iron chelators inhibit human platelet aggregation, thromboxane A synthesis and lipoxygenase activity. FEBS Lett 245,105-109 (1989)
77. Sadrzadeh, S.M., A.A.Nanji, and P.L. Price: The oral iron chelator, 1,2-dimethyl-3-hydroxypyrid-4-one reduces hepatic-free iron, lipid peroxidation and fat accumulation in chronically ethanol-fed rats. J Pharmacol Exp Ther 269, 632-636 (1994)
78. Crosland, R.D.: Action of reactive oxygen species and their antagonists on twitch tension of the rat phrenic nervediaphragm. Pharmacol Toxicol 77, 231-237 (1995)
79. Arthur, A.S., A.H. Fergus, G. Lanzino, J. Mathys, N.F. Kassell, and K.S. Lee: Systemic administration of the iron chelator deferiprone attenuates subarachnoid hemorrhage induced cerebral vasospasm in the rabbit. Neurosurgery 41,1385-1391 (1997)
80. Ablin, J., O. Shalev, E. Okon, F. Karmeli and D. Rachmilewitz: Deferiprone, an oral iron chelator, ameliorates experimental colitis and gastric ulceration in rats. Inflamm Bowel Dis 5, 253-261 (1999)
81. Minaiyan, M., Mostaghel E, and Mahzouni P: Preventive therapy of experimental colitis with selected iron chelators and anti-oxidants. Int J Prev Med. 3, S162-9 (2012)
82. Waldmeier, P.C., A. M. Buchle, and A.F. Steulet: Inhibition of catechol-O-methyltransferase (COMT) as well as tyrosine and tryptophan hydroxylase by the orally active iron chelator, 1,2-dimethyl-3-hydroxypyridin-4- one (L1, CP20), in rat brain in vivo. Biochem Pharmacol 45, 2417-2424 (1993)
83. Eybl, V., D. Kotyzova, M. Kolek, J. Koutensky, and P. Nielsen: The influence of deferiprone (L1) and deferoxamine on iron and essential element tissue level and parameters of oxidative status in dietary iron-loaded mice. Toxicol Lett 128, 169-175 (2002)
84. Eybl, V., D. Caisová J. Koutenský, and G.J. Kontoghiorghes: Influence of iron chelators, 1,2-dialkyl-3-hydroxypyridin-4-ones, on the lipid peroxidation and glutathione level in the liver of mice. Arch Toxicol Suppl 14,185-187(1991)
85. Hodková, A., P. Cerná, D. Kotyzová, and V.Eybl: The effect of iron (III) on the activity of selenoenzymes and oxidative damage in the liver of rats. Interaction with natural antioxidants and deferiprone. Hemoglobin 34:278-283 (2010)
86. Lai, H., and N.P. Singh: Magnetic-field-induced DNA strand breaks in brain cells of the rat. Environ Health Perspect 112, A726 (2004)
87. Xu, L.J., L.Jin, H. Pan, A.Z., G. Wei P.P. Li and W.Y.Lu: Deferiprone protects the isolated atria from cardiotoxicity induced by doxorubicin. Acta Pharmacol Sin 27, 1333-1339 (2006)
88. Cerná, P., D. Kotyzová, and V. Eybl: The effect of the oral iron chelator deferiprone on the liver damage induced by tamoxifen in female rats. Hemoglobin 35, 255-261(2011)
89. Mitchell, K.M., A.L. Dotson, K.M. Cool, A. Chakraparty, S. H. Benedict, and S. M. Levine: Deferiprone, an orally deliverable iron chelator, ameliorates experimental autoimmune encephalomyelitis. Mult Scler 13, 1118-1126 (2007)
90. Gorman, N., A. Zaharia, H. S. Trask, J.G. Szakacs, N.J. Jacobs, J.M.Jacobs, D. Balestra, J.F.Sinclair, and P.R. Sinclair: Effect of an oral iron chelator or iron-deficient diets on uroporphyria in a murine model of porphyria cutanea tarda. Hepatology 46,1927-1034 (2007)
91. Matthews, A.J., G.M. Vercellotti, H.J. Menchaca, P.H. Bloch, V.N.Michalek P.H. Marker, J.Murarand, and H. Buchwald: Iron and atherosclerosis: Inhibition by the iron chelator deferiprone (L1) J Surg Res 73, 35-40 (1997)
92. Mohammadpour, M., M. Behjati, A. Sadeghi, and A. Fassihi: Wound healing by topical application of antioxidant iron chelators: kojic acid and deferiprone. Int Wound J. 10, 260-264 (2013)
93. Lu, J., D. Gong, S.Y. Choong, H. Xu, Y.K. Chan, X. Chen, S. Fitzpatrick, S. Glyn-Jones, S. Zhang, T. Nakamura, K. Ruggiero, V. Obolonkin, S.D. Poppitt, A.R. Phillips, and G.J. Cooper: Copper (II)-selective chelation improves function and antioxidant defences in cardiovascular tissues of rats as a model of diabetes: comparisons between triethylenetetramine and three less copper-selective transition-metal-targeted treatments. Diabetologia 53,1217-1226 (2010)
94. Jeremy, J.Y., J. Gill and G.J. Kontoghiorghes: Copper chelators inhibit platelet thromboxane A2 synthesis and lipoxygenase activity in vitro. J Dr Dev Clin Prac 7, 119-121(1995)
95. Filosa, A., L. Valgimigli, G.F. Pedulli, A. Sapone, A. Maggio, D. Renda, C. Scazzone, R. Malizia, L. Pitrolo, C. Lo Pinto, Z. Borsellino, L. Cuccia, M. Capra, D. Canistro, M. Broccoli, A. Soleti, and M. Paolini: Quantitative evaluation of oxidative stress status on peripheral blood in beta-thalassaemic patients by means of electron paramagnetic resonance spectroscopy. Br J Haematol.13,135-140 (2005)
96. Kontoghiorghes, G.J., M.A.Aldouri, L.N.Sheppard, and A.V. Hoffbrand: 1, 2- Dimethyl-3-hydroxypyrid-4-one, on orally active chelator for the treatment of transfusional iron overload. Lancet I, 1294-1295 (1987)
97. Kolnagou, A., and G.J. Kontoghiorghes: Effective combination therapy of deferiprone and deferoxamine for the rapid clearance of excess cardiac iron and prevention of heart disease in thalassaemia. The protocol of the international committee on oral chelators. Hemoglobin 30, 239-249 (2006)
98. Kontoghiorghe, C.N., Kolnagou, A., and G.J. Kontoghiorghes. Potential clinical applications of chelating drugs in diseases targeting transferrin-bound iron and other metals. Expert Opin Investig Drugs 22, 591-618 (2013)
99. Kontoghiorghes, G.J., and A. Kolnagou: Deferiprone versus desferrioxamine in thalassaemia, and T2&z.ast; validation and utility. Lancet 361,184 (2003)
100. Vreugdenhil, G., G.J. Kontoghiorghes, H.G.Van Eijk, and A.J.G. Swaak: Impaired erythropoietin responsiveness to the anemia in rheumatoid arthritis. A possible inverse relationship with iron stores and effects of the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one. Clin Exp Rheumatol 9, 35-40 (1991)
101. Vreughtenhil, G., G.J. Kontoghiorghes, H.G.Van Eijk, and A.J.G. Swaak: Efficacy and safety of the oral chelator L1 in anaemic rheumadoit arthritis patients. Lancet II, 1398-1399 (1989)
102. Boddaert N., K.H. Le Quan Sang, A. Rotig, A. Leroy-Willig, S. Gallet, F. Brunelle, D. Sidi, J.C. Thalabard, A. Munnich, and Z.I. Cabantchik: Selective iron chelation in Friedreich ataxia: biologic and clinical implications. Blood 110, 401-408 (2007)
103. Rajapurkar, M.M., R. Beliga, and S. Shah: Treatment of patients with glomerulonephritis with an oral iron chelator. J Am Soc Nephrol 18, 57-58A (2007)
104. Rajapurkar, M.M., M.G. Alam, A. Bhattacharya, and S. Shah: Novel treatment for diabetic nephropathy. J Am Soc Nephrol 18, 329A (2007)
105. Rajapurkar, M.M., U. Hegde, A. Bhattacharya, M.G. Alam, and S.V. Shah: Effect of deferiprone, an oral iron chelator, in diabetic and non-diabetic glomerular disease. Toxicol Mech Methods 23, 5-10 (2013)
106. Britton, R.S., K.L. Leicester, and B.R. Bacon.: Iron toxicity and chelation therapy. Int J Haematol 76, 219-228 (2002)
107. Kolnagou, A., Y. Michaelids, C. Kontos, K. Kyriacou, and G.J. Kontoghiorghes: Myocyte damage and loss of myofibers is the potential mechanism of iron overload toxicity in congestive cardiac failure in thalasssaemia. Complete reversal of the cardiomyopathy and normalisation of iron load by deferiprone. Hemoglobin 32,17-28 (2008)
108. Breuer, W., C. Hershko, and Z.I. Cabantchik: The importance of non-transferrin bound iron in disorders of iron metabolism. Transf Sc 23, 185-192 (2000)
109. Bartfay, W.J., D.C. Lehotay, G.D. Sher, E. Bartfay, B. Tyler, X. Luo, and P.P.Liu: Erythropoiesis: Comparison of cytotoxic aldehyde generation in beta-thalassemia patients chelated with deferoxamine or deferiprone (L1) versus no chelation. Hepatology 4, 67-76 (1999)
110. Platis, O., G. Anagnostopoulos, K. Farmaki, M. Posantzis, E. Gotsis, and G. Tolis: Glucose metabolism disorders improvement in patients with thalassaemia major after 24-36 months of intensive chelation therapy. Pediatr Endocrinol Rev 2, 279-281 (2004)
111. Lodi, R., P.E. Hart, B. Rajagopalana, D.J. Taylor, J.D. Grilley, J.L. Bradley, A.M. Blamire, D. Manners, P.Styles, A.H. Schapira, and J. M. Cooper: Antioxidant treatment improves in vivo cardiac and skeletal muscle bioenergetics in patients with Friedreich's ataxia. Ann Neurol 49: 590-596 (2001)
112. Koeppen, A.H., and A.C. Dickson: Iron in the Hallervorden-Spatz syndrome. Pediatric Neurolog. 25, 148-155 (2001)
113. Pootrakul, P., P.Sirankapracha, J. Sankote, U. Kachintorn, W. Maunqsub, K. Sriphen, K. Thakernpol, K. Atisuk, S. Fuchareon, U. Chantraluksri, O. Shalev, and A. V. Hoffbrand: Clinical trial of deferiprone iron chelation therapy in beta-thalassaemia/haemoglobin E patients in Thailand. Br J Haematol 122, 305-310 (2003)
114. Chang, Y.H., C.F. Shaw, K.H. Wu, K.H. Hsieh, Y.N. Su, and P.J. Lu: Treatment with deferiprone for iron overload alleviates bone marrow failure in a Fanconi anemia patient. Hemoglobin 33, 346-351(2009)
115. Farmaki, K., I. Tzoumari, C. Pappa, G. Chouliaras, and V. Berdoukas: Normalisation of total body iron load with very intensive combined chelation reverses cardiac and endocrine complications of thalassaemia major. Br J Haematol 148, 466-75 (2010)
116. Fredenburg, A.M., R.K. Sethi, D.D. Allen, and R.A. Yokel: The pharmacokinetics and blood-brain barrier permeation of the chelators 1,2-dimethyl-,1,2-diethyl-, and 1-[ethan-1-ol]-2-methyl-3-hydroxypyridin-4-one in the rat. Toxicology 108, 191-199 (1996)
117. Kolnagou, A., C. Economides, E. Eracleous, and G.J. Kontoghiorghes: Low serum ferritin levels are misleading for detecting cardiac iron overload and increase the risk of cardiomyopathy in thalassemia patients. The importance of cardiac iron overload monitoring using magnetic resonance imaging T2 and T2&z.ast;. Hemoglobin. 30, 219-227 (2006)
118. Tanner, M.A., R. Galanello, C. Dessi, G.C. Smith, M.A. Westwood, A. Agus, M. Roughton, R. Assomull, S.V. Nair, J.M. Walker, and D.J. Pennell: A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance. Circulation 115,1876-1884 (2007)
119. Filosa, A., A. Vitrano, P. Rigano, G. Calvaruso, R. Barone, M. Capra, L. Cuccia, F. Gagliardotto, L. Pitrolo, L. Prossomariti, M. Casale, V. Caruso, C. Gerardi, S. Campisi, P. Cianciulli, M. Rizzo, G. D'Ascola, A.Ciancio, and A. Maggio: Long-term treatment with deferiprone enhances left ventricular ejection function when compared to deferoxamine in patients with thalassemia major. Blood Cells Mol Dis 51:85-88 (2013)
120. Forni, G.L., M. Balocco, L. Cremonesi, G. Abbruzzese, R.C. Parodi, and R. Marchese: Regression of symptoms after selective iron chelation therapy in a case of neurodegeneration with brain iron accumulation. Mov Disord. 23, 904-907 (2008)
121. Abbruzzese, G., G. Cossu, M. Balocco, R. Marchese, D. Murgia, M. Melis, R. Galanello, S. Barella, G. Matta, U. Ruffinengo, U. Bonuccelli, and G.L. Forni: A pilot trial of deferiprone for neurodegeneration with brain iron accumulation. Haematologica 96, 1708-1711 (2011)
122. Kolnagou, A., M. Kleanthous, and G.J. Kontoghiorghes: Reduction of body iron stores to normal range levels in thalassaemia by using a deferiprone/deferoxamine combination and their maintenance thereafter by deferiprone monotherapy. Eur J Haematol 85, 430-438 (2010)
123. Kolnagou, A., and G.J. Kontoghiorghes: Maintenance of normal range body iron store levels for up to 4.5 years in thalassemia major patients using deferiprone monotherapy. Hemoglobin 34, 204-209 (2010)
124. Kolnagou, A., and G.J. Kontoghiorghes: New golden era of chelation therapy in thalassaemia: the achievement and maintenance of normal range body iron stores. Br J Haematol 150, 489-490 (2010)
125. Kontoghiorghes, G.J., A. Kolnagou, C.T. Peng, S.V. Shah, and A. Aessopos: Safety issues of iron chelation therapy in patients with normal range iron stores including thalassaemia, neurodegenerative, renal and infectious diseases. Expert Opin Drug Saf. 9, 201-206 (2010)
126. ClinicalTrials.gov: NCT00943748 Health Authority: France: Afssaps-French Health Products Safety Agency. Availble from http:// clinicaltrials.gov/show/ NCT00943748; Study ID Number: 2008-006842-25
127. Arkadopoulos, N., C. Nastos, K. Kalimeris, E. Economou, K. Theodoraki, E. Kouskouni, A. Pafiti, G. Kostopanagiotou, and V. Smyrniotis: Iron chelation for amelioration of liver ischemia-reperfusion injury. Hemoglobin 34, 265-277 (2010)
128. Forni, G.L., D. Girelli, M. Lamagna, M. Mori, E. Marinaro, N. Campostrini, P. Carrara, and M. Maffei: Acquired iron overload associated with antitransferrin monoclonal immunoglobulin: a case report. Am J Hematol. 83, 932-934 (2008)
129. Markelic, M., K. Velickovic, I. Golic, W. Klepal, V. Otasevic, A. Stancic, A. Jankovic, M. Vucetic, B. Buzadzic, B. Korac and A. Korac: The origin of lipofuscin in brown adipocytes of hyperinsulinaemic rats: the role of lipid peroxidation and iron. Histol Histopathol 28, 493-503 (2013)
130. Velasco-Sánchez, D., A. Aracil, R. Montero, A. Mas, L. Jiménez, M. O'Callaghan, M. Tondo, A. Capdevila, J. Blanch, R. Artuch, and M. Pineda: Combined therapy with idebenone and deferiprone in patients with Friedreich's ataxia. Cerebellum 10, 1-8 (2011)
131. Topic, A., D. Francuski, B. Markovic, M. Stankovic, S. Dobrivojevic, S. Drca, and D. Radojkovic: Gender-related reference intervals of urinary 8-oxo-7,8-dihydro-2′- deoxyguanosine determined by liquid chromatography-tandem mass spectrometry in Serbian population. Clin Biochem. 46,321-326 (2013)